Autres langues Clinuvel Pharmaceuticals Limited Deutsche Boerse AG

Actions

UR9

AU000000CUV3

Produits pharmaceutiques

Temps réel estimé Tradegate Autres places de cotation 09:30:33 04/08/2026			Varia. 5j.	Varia. 1 janv.
5,467 ^EUR	+3,15%		-10,17%	-24,29%

30/07	Clinuvel Pharmaceuticals renforce sa chaîne d'approvisionnement en vue du lancement sur le marché nord-américain du vitiligo	MT
28/07	Clinuvel Pharmaceuticals Ltd fait le point sur le SCENESSE dans le traitement du vitiligo	CI

Autres langues

30/07	Clinuvel Pharmaceuticals Strengthens Supply Chain as Part of Commercial Preparations for North American Vitiligo Market
28/07	Clinuvel Pharmaceuticals Ltd Provides Update On SCENESSE In Vitiligo
28/07	Clinuvel Pharmaceuticals Plans to Report Late-Stage Vitiligo Study Topline Results in December
23/07	Clinuvel Pharmaceuticals Limited to Reduce Global Workforce by Approximately 10%-20%
23/07	Clinuvel Pharmaceuticals Limited Announces Relocation of Corporate Headquarters to the United States
23/07	CLINUVEL implements strategic reorganisation to refocus on U.S. markets
23/07	Clinuvel Pharmaceuticals to Move Headquarters to US, Plan Workforce Reduction of Up to 20%
23/07	Australian Shares Open Higher as Oil, Gold Rally on Middle East Tensions; Santos Posts Higher Q2 Total Production
21/07	Clinuvel Pharmaceuticals Confirms ADS Start Trading on Nasdaq
21/07	Clinuvel Pharmaceuticals Limited(NasdaqGS:CUVL) added to NASDAQ Composite Index
20/07	CLINUVEL’s ADS to commence trading on Nasdaq
20/07	Clinuvel Pharmaceuticals' ADS to Begin Trading on Nasdaq
13/07	Clinuvel Pharmaceuticals Limited Receives Health Canada Notice of Compliance for Scenesse for Prevention of Phototoxicity in Adult Patients with Erythropoietic Protoporphyria
13/07	SCENESSE® approved for EPP in Canada
13/07	Clinuvel Pharmaceuticals' Photoprotection Drug Candidate Receives Health Canada Approval
02/07	Clinuvel Pharmaceuticals Extends CEO Philippe Wolgen's Term of Employment
16/06	Clinuvel Pharmaceuticals Advances US Listing Plan With SEC Filing for Nasdaq ADS Upgrade
28/04	Clinuvel Pharmaceuticals plans level II ADR upgrade and Nasdaq listing as CUVL
28/04	Clinuvel Pharmaceuticals Advances Nasdaq ADR Uplisting With US SEC Review Underway
27/04	Clinuvel Pharmaceuticals says FDA relaxes Scenesse postmarketing requirement
27/04	Clinuvel Pharmaceuticals Says FDA Removes Post-Authorization Requirement for Implant
27/04	Clinuvel Unlikely to Seek Scenesse's Vitiligo Approval Before Phase 3 Completion, Says Jefferies
24/04	Clinuvel Pharmaceuticals Limited Receives Final European Scientific Advice for Pivotal Phase III Vitiligo Study
24/04	CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study
24/04	Clinuvel Pharmaceuticals receives final EMA scientific advice for pivotal phase III vitiligo study